[Progress in endocrine therapy for early breast cancer]

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Nov 28;44(11):1268-1274. doi: 10.11817/j.issn.1672-7347.2019.190289.
[Article in Chinese]

Abstract

Breast cancer is a malignant tumor that occurs in the epithelial tissues of the breast gland. The cause of the disease is not fully understood and may be related to genetic, endocrine and other factors. For estrogen or progesterone receptor-positive early breast cancer, endocrine therapy is efficient, simple, and fewer side-effect, so endocrine therapy plays an important role in the treatment for early breast cancer. But most of them will develop drug-resistant after 8 to 14 months and have to combine with chemotherapy or molecule targeted therapy. However, there are still different ideas in the effects of endocrine therapy drugs alone or in combination with chemotherapy or molecule targeted drugs, pre-menopausally or post-menopausally.

乳腺癌是发生在乳腺腺上皮组织中的恶性肿瘤,其病因尚未完全清楚,可能与遗传及内分泌等因素相关。针对激素受体阳性的早期乳腺癌,内分泌治疗疗效显著,且服用便捷,不良反应小,因此内分泌治疗在早期乳腺癌治疗中占重要地位。但大部分患者在8~14个月后会发展为药物耐药,不得不寻求化学药物治疗或靶向治疗。目前对于内分泌治疗药物与化学药物治疗或靶向药物联合用药的效果尚存在分歧,而且绝经前后用药亦有很大差异。.

MeSH terms

  • Breast Neoplasms*
  • Humans
  • Receptors, Estrogen

Substances

  • Receptors, Estrogen